MicroRNA-128a dysregulation in transgenic Huntington's disease monkeys

Molecular Brain

Volumn 7, Issue 1, 2014, Pages

  Kocerha, Jannet ^a,b,c   Xu, Yan ^a,b   Prucha, Melinda S ^a,b   Zhao, Dongming ^a,b   Chan, Anthony W S ^a,b  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c GEORGIA SOUTHERN UNIVERSITY   (United States)

Author keywords

Brain; Huntington's disease; microRNAs; miR 128a; Noncoding RNAs

Indexed keywords

CASPASE 3; GLIAL FIBRILLARY ACIDIC PROTEIN; HUNTINGTIN; HUNTINGTIN INTERACTION PROTEIN 1; MICRORNA; MICRORNA 128A; PROTEIN; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FRONTAL CORTEX; GENE TARGETING; GENOTYPE; HAPLORHINI; HUNTINGTON CHOREA; MONKEY MODEL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; GENE CONTROL; GENE EXPRESSION; HUMAN; MOUSE; TRANSGENIC ANIMAL;

MUS; PRIMATES;

3' UNTRANSLATED REGIONS; ANIMALS; ANIMALS, GENETICALLY MODIFIED; CASPASE 3; ENZYME ACTIVATION; FRONTAL LOBE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENOTYPING TECHNIQUES; GLIAL FIBRILLARY ACIDIC PROTEIN; HAPLORHINI; HEK293 CELLS; HUMANS; HUNTINGTON DISEASE; MICE; MICRORNAS; NERVE TISSUE PROTEINS; PROTEIN STRUCTURE, QUATERNARY; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 84902068601     PISSN: None     EISSN: 17566606     Source Type: Journal    
DOI: 10.1186/1756-6606-7-46     Document Type: Article

References (54)

1. MicroRNAs: target recognition and regulatory functions. Bartel DP, Cell 2009 136 215 233 10.1016/j.cell.2009.01.002 19167326
2. MicroRNA dysregulation in schizophrenia. Beveridge NJ, Cairns MJ, Neurobiol Dis 2012 46 263 271 10.1016/j.nbd.2011.12.029 22207190
3. MicroRNA regulation of neural stem cells and neurogenesis. Shi Y, Zhao X, Hsieh J, Wichterle H, Impey S, Banerjee S, Neveu P, Kosik KS, J Neurosci 2010 30 14931 14936 10.1523/JNEUROSCI.4280-10.2010 21068294
4. Context-dependent functions of specific microRNAs in neuronal development. Gao FB, Neural Dev 2010 5 25 10.1186/1749-8104-5-25 20920300
5. MicroRNA function in the nervous system. Fiore R, Khudayberdiev S, Saba R, Schratt G, Prog Mol Biol Transl Sci 2011 102 47 100 21846569
6. MicroRNA pathways in neural development and plasticity. Vo NK, Cambronne XA, Goodman RH, Curr Opin Neurobiol 2010 20 457 465 10.1016/j.conb.2010.04.002 20447821
7. Roles of small regulatory RNAs in determining neuronal identity. Li X, Jin P, Nat Rev Neurosci 2010 11 329 338 10.1038/nrn2739 20354535
8. MicroRNAs in neuronal function and dysfunction. Im HI, Kenny PJ, Trends Neurosci 2012 35 325 334 10.1016/j.tins.2012.01.004 22436491
9. microRNAs in CNS disorders. Kocerha J, Kauppinen S, Wahlestedt C, Neuromolecular Med 2009 11 162 172 10.1007/s12017-009-8066-1 19536656
10. Schizophrenia is associated with an increase in cortical microRNA biogenesis. Beveridge NJ, Gardiner E, Carroll AP, Tooney PA, Cairns MJ, Mol Psychiatry 2010 15 1176 1189 10.1038/mp.2009.84 19721432
11. MicroRNA-219 modulates NMDA receptor-mediated neurobehavioral dysfunction. Kocerha J, Faghihi MA, Lopez-Toledano MA, Huang J, Ramsey AJ, Caron MG, Sales N, Willoughby D, Elmen J, Hansen HF, Orum H, Kauppinen S, Kenny PJ, Wahlestedt C, Proc Natl Acad Sci U S A 2009 106 3507 3512 10.1073/pnas. 0805854106 19196972
12. Altered microRNA expression in frontotemporal lobar degeneration with TDP-43 pathology caused by progranulin mutations. Kocerha J, Kouri N, Baker M, Finch N, DeJesus-Hernandez M, Gonzalez J, Chidamparam K, Josephs KA, Boeve BF, Graff-Radford NR, Crook J, Dickson DW, Rademakers R, BMC Genomics 2011 12 527 10.1186/1471-2164-12-527 22032330
13. Striatal microRNA controls cocaine intake through CREB signalling. Hollander JA, Im HI, Amelio AL, Kocerha J, Bali P, Lu Q, Willoughby D, Wahlestedt C, Conkright MD, Kenny PJ, Nature 2010 466 197 202 10.1038/nature09202 20613834
14. MicroRNAs in Parkinson's disease. Mouradian MM, Neurobiol Dis 2012 46 279 284 10.1016/j.nbd.2011.12.046 22245218
15. Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/beta-secretase expression. Hebert SS, Horre K, Nicolai L, Papadopoulou AS, Mandemakers W, Silahtaroglu AN, Kauppinen S, Delacourte A, De Strooper B, Proc Natl Acad Sci U S A 2008 105 6415 6420 10.1073/pnas.0710263105 18434550
16. RNA and microRNAs in fragile X mental retardation. Jin P, Alisch RS, Warren ST, Nat Cell Biol 2004 6 1048 1053 10.1038/ncb1104-1048 15516998
17. The Emerging Role of microRNAs in Schizophrenia and Autism Spectrum Disorders. Mellios N, Sur M, Front Psychiatry 2012 3 39 22539927
18. The Path to microRNA Therapeutics in Psychiatric and Neurodegenerative Disorders. Chan AW, Kocerha J, Front Genet 2012 3 82 22629284
19. Huntington's disease: from molecular pathogenesis to clinical treatment. Ross CA, Tabrizi SJ, Lancet Neurol 2011 10 83 98 10.1016/S1474-4422(10)70245-3 21163446
20. Death of neuronal clusters contributes to variance of age at onset in Huntington's disease. Cajavec B, Herzel H, Bernard S, Neurogenetics 2006 7 21 25 10.1007/s10048-005-0025-x 16416264
21. Juvenile Huntington's disease: does a dosage-effect pathogenic mechanism differ from the classical adult disease? Squitieri F, Frati L, Ciarmiello A, Lastoria S, Quarrell O, Mech Ageing Dev 2006 127 208 212 10.1016/j.mad.2005.09. 012 16274727
22. Hsa-miR-34b is a plasma-stable microRNA that is elevated in pre-manifest Huntington's disease. Gaughwin PM, Ciesla M, Lahiri N, Tabrizi SJ, Brundin P, Bjorkqvist M, Hum Mol Genet 2011 20 2225 2237 10.1093/hmg/ddr111 21421997
23. Altered microRNA regulation in Huntington's disease models. Lee ST, Chu K, Im WS, Yoon HJ, Im JY, Park JE, Park KH, Jung KH, Lee SK, Kim M, Roh JK, Exp Neurol 2011 227 172 179 10.1016/j.expneurol.2010.10.012 21035445
24. A myriad of miRNA variants in control and Huntington's disease brain regions detected by massively parallel sequencing. Marti E, Pantano L, Banez-Coronel M, Llorens F, Minones-Moyano E, Porta S, Sumoy L, Ferrer I, Estivill X, Nucleic Acids Res 2010 38 7219 7235 10.1093/nar/gkq575 20591823
25. The bifunctional microRNA miR-9/miR-9* regulates REST and CoREST and is downregulated in Huntington's disease. Packer AN, Xing Y, Harper SQ, Jones L, Davidson BL, J Neurosci 2008 28 14341 14346 10.1523/JNEUROSCI.2390-08. 2008 19118166
26. MicroRNA-22 (miR-22) overexpression is neuroprotective via general anti-apoptotic effects and may also target specific Huntington's disease-related mechanisms. Jovicic A, Zaldivar Jolissaint JF, Moser R, Silva Santos Mde F, Luthi-Carter R, PLoS One 2013 8 54222 10.1371/journal.pone.0054222 23349832
27. Dysregulation of REST-regulated coding and non-coding RNAs in a cellular model of Huntington's disease. Soldati C, Bithell A, Johnston C, Wong KY, Stanton LW, Buckley NJ, J Neurochem 2013 124 418 430 10.1111/jnc.12090 23145961
28. Interrogation of brain miRNA and mRNA expression profiles reveals a molecular regulatory network that is perturbed by mutant huntingtin. Jin J, Cheng Y, Zhang Y, Wood W, Peng Q, Hutchison E, Mattson MP, Becker KG, Duan W, J Neurochem 2012 123 477 490 10.1111/j.1471-4159.2012.07925.x 22906125
29. Longitudinal transcriptomic dysregulation in the peripheral blood of transgenic Huntington's disease monkeys. Kocerha J, Liu Y, Willoughby D, Chidamparam K, Benito J, Nelson K, Xu Y, Chi T, Engelhardt H, Moran S, Yang SH, Li SH, Li XJ, Larkin K, Neumann A, Banta H, Yang JJ, Chan AW, BMC Neurosci 2013 14 88 10.1186/1471-2202-14-88 23957861
30. Pathogenic cellular phenotypes are germline transmissible in a transgenic primate model of Huntington's disease. Putkhao K, Kocerha J, Cho IK, Yang J, Parnpai R, Chan AW, Stem Cells Dev 2013 22 1198 1205 10.1089/scd.2012.0469 23190281
31. Full-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expression. Pouladi MA, Xie Y, Skotte NH, Ehrnhoefer DE, Graham RK, Kim JE, Bissada N, Yang XW, Paganetti P, Friedlander RM, Leavitt BR, Hayden MR, Hum Mol Genet 2010 19 1528 1538 10.1093/hmg/ddq026 20097678
32. IRS2 increases mitochondrial dysfunction and oxidative stress in a mouse model of Huntington disease. Sadagurski M, Cheng Z, Rozzo A, Palazzolo I, Kelley GR, Dong X, Krainc D, White MF, J Clin Invest 2011 121 4070 4081 10.1172/JCI46305 21926467
33. The insulin paradox: aging, proteotoxicity and neurodegeneration. Cohen E, Dillin A, Nat Rev Neurosci 2008 9 759 767 10.1038/nrn2474 18769445
34. MiR-128 up-regulation inhibits Reelin and DCX expression and reduces neuroblastoma cell motility and invasiveness. Evangelisti C, Florian MC, Massimi I, Dominici C, Giannini G, Galardi S, Bue MC, Massalini S, McDowell HP, Messi E, Gulino A, Farace MG, Ciafrè SA, FASEB J 2009 23 4276 4287 10.1096/fj.09-134965 19713529
35. Pro-neural miR-128 is a glioma tumor suppressor that targets mitogenic kinases. Papagiannakopoulos T, Friedmann-Morvinski D, Neveu P, Dugas JC, Gill RM, Huillard E, Liu C, Zong H, Rowitch DH, Barres BA, Verma IM, Kosik KS, Oncogene 2012 31 1884 1895 10.1038/onc.2011.380 21874051
36. MicroRNA-128 governs neuronal excitability and motor behavior in mice. Tan CL, Plotkin JL, Veno MT, Von Schimmelmann M, Feinberg P, Mann S, Handler A, Kjems J, Surmeier DJ, O'Carroll D, Greengard P, Schaefer A, Science 2013 342 1254 1258 10.1126/science.1244193 24311694
37. Seizures in juvenile Huntington's disease: frequency and characterization in a multicenter cohort. Cloud LJ, Rosenblatt A, Margolis RL, Ross CA, Pillai JA, Corey-Bloom J, Tully HM, Bird T, Panegyres PK, Nichter CA, Higgins DS Jr, Helmers SL, Factor SA, Jones R, Testa CM, Mov Disord 2012 27 1797 1800 10.1002/mds.25237 23124580
38. A systematic review and meta-analysis of clinical variables used in Huntington disease research. Franciosi S, Shim Y, Lau M, Hayden MR, Leavitt BR, Mov Disord 2013 28 1987 1994 10.1002/mds.25663 24142393
39. Ablation of D1 dopamine receptor-expressing cells generates mice with seizures, dystonia, hyperactivity, and impaired oral behavior. Gantois I, Fang K, Jiang L, Babovic D, Lawrence AJ, Ferreri V, Teper Y, Jupp B, Ziebell J, Morganti-Kossmann CM, O'Brien TJ, Nally R, Schütz G, Waddington J, Egan GF, Drago J, Proc Natl Acad Sci U S A 2007 104 4182 4187 10.1073/pnas.0611625104 17360497
40. miR-128 exerts pro-apoptotic effect in a p53 transcription-dependent and -independent manner via PUMA-Bak axis. Adlakha YK, Saini N, Cell Death Dis 2013 4 542 10.1038/cddis.2013.46 23492773
41. MicroRNA-128 downregulates Bax and induces apoptosis in human embryonic kidney cells. Adlakha YK, Saini N, Cell Mol Life Sci 2011 68 1415 1428 10.1007/s00018-010-0528-y 20924637
42. Evidence of apoptosis and mitochondrial abnormalities in peripheral blood cells of Huntington's disease patients. Almeida S, Sarmento-Ribeiro AB, Januario C, Rego AC, Oliveira CR, Biochem Biophys Res Commun 2008 374 599 603 10.1016/j.bbrc.2008.07.009 18625199
43. Increase in bax expression and apoptosis are associated in Huntington's disease progression. Teles AV, Rosenstock TR, Okuno CS, Lopes GS, Bertoncini CR, Smaili SS, Neurosci Lett 2008 438 59 63 10.1016/j.neulet.2008.03.062 18468793
44. Expression of Huntington's disease protein results in apoptotic neurons in the brains of cloned transgenic pigs. Yang D, Wang CE, Zhao B, Li W, Ouyang Z, Liu Z, Yang H, Fan P, O'Neill A, Gu W, Yi H, Li S, Lai L, Li XJ, Hum Mol Genet 2010 19 3983 3994 10.1093/hmg/ddq313 20660116
45. Huntington's disease: roles of huntingtin-interacting protein 1 (HIP-1) and its molecular partner HIPPI in the regulation of apoptosis and transcription. Bhattacharyya NP, Banerjee M, Majumder P, FEBS J 2008 275 4271 4279 10.1111/j.1742-4658.2008.06563.x 18637945
46. Neuronal caspase-3 signaling: not only cell death. D'Amelio M, Cavallucci V, Cecconi F, Cell Death Differ 2010 17 1104 1114 10.1038/cdd.2009.180 19960023
47. Caspase-3 activation is a critical determinant of genotoxic stress-induced apoptosis. Mazumder S, Plesca D, Almasan A, Methods Mol Biol 2008 414 13 21 18175808
48. Allele variants in functional MicroRNA target sites of the neurotrophin-3 receptor gene (NTRK3) as susceptibility factors for anxiety disorders. Muinos-Gimeno M, Guidi M, Kagerbauer B, Martin-Santos R, Navines R, Alonso P, Menchon JM, Gratacos M, Estivill X, Espinosa-Parrilla Y, Hum Mutat 2009 30 1062 1071 10.1002/humu.21005 19370765
49. Overexpression of miR-128 specifically inhibits the truncated isoform of NTRK3 and upregulates BCL2 in SH-SY5Y neuroblastoma cells. Guidi M, Muinos-Gimeno M, Kagerbauer B, Marti E, Estivill X, Espinosa-Parrilla Y, BMC Mol Biol 2010 11 95 10.1186/1471-2199-11-95 21143953
50. MicroRNA-128 inhibits glioma cells proliferation by targeting transcription factor E2F3a. Zhang Y, Chao T, Li R, Liu W, Chen Y, Yan X, Gong Y, Yin B, Qiang B, Zhao J, Yuan J, Peng X, J Mol Med 2009 87 43 51 10.1007/s00109-008-0403-6 18810376
51. Nonsense-mediated mRNA decay: inter-individual variability and human disease. Nguyen LS, Wilkinson MF, Gecz J, Neurosci Biobehav Rev 2013 doi:10.1016/j.neubiorev.2013.10.016. [Epub ahead of print]
52. Identification of a microRNA that activates gene expression by repressing nonsense-mediated RNA decay. Bruno IG, Karam R, Huang L, Bhardwaj A, Lou CH, Shum EY, Song HW, Corbett MA, Gifford WD, Gecz J, Pfaff SL, Wilkinson MF, Mol Cell 2011 42 500 510 10.1016/j.molcel.2011.04.018 21596314
53. Towards a transgenic model of Huntington's disease in a non-human primate. Yang SH, Cheng PH, Banta H, Piotrowska-Nitsche K, Yang JJ, Cheng EC, Snyder B, Larkin K, Liu J, Orkin J, Fang ZH, Smith Y, Bachevalier J, Zola SM, Li SH, Li XJ, Chan AW, Nature 2008 453 921 924 10.1038/nature06975 18488016
54. Accumulation of N-terminal mutant huntingtin in mouse and monkey models implicated as a pathogenic mechanism in Huntington's disease. Wang CE, Tydlacka S, Orr AL, Yang SH, Graham RK, Hayden MR, Li S, Chan AW, Li XJ, Hum Mol Genet 2008 17 2738 2751 10.1093/hmg/ddn175 18558632